Volume 2.04 | Feb 4

Prostate Cell News 2.04, February 4, 2011.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe

TOP STORY

Dana-Farber Researchers Identify Molecular Predictor of Metastatic Prostate Cancer  ShareThis
Prostate tumors that carry a “signature” of four molecular markers have the potential to become dangerously metastatic if not treated aggressively, researchers report. [Press release from the Dana-Farber Cancer Institute discussing online prepublication in Nature]

ON134_645x110


SPECIAL FEATURE

Facebook Cell Therapy News is now on Facebook. Join us! 

Twitter Follow us on Twitter! @ProstateCell

Interested in recruiting talented individuals? Post your career opportunities in Prostate Cell News at no cost. Contact us at [email protected]



SCIENCE NEWS

Inovio Pharmaceuticals’ Dual-Antigen SynCon(TM) DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial
Inovio Pharmaceuticals, Inc. announced the publication of a scientific paper detailing potent immune responses in a preclinical study of Inovio’s SynCon(TM) DNA vaccine for prostate cancer targeting two antigens. [Press release from Inovio Pharmaceuticals, Inc. discussing online prepublication in Human Vaccine]

ON137_SocialMedia_645x110


CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

SMAD4-Dependent Barrier Constrains Prostate Cancer Growth and Metastatic Progression
Here, researchers exploited the experimental merits of the mouse to test the hypothesis that pathways constraining progression might be activated in indolent Pten-null mouse prostate tumours and that inactivation of such progression barriers in mice would engender a metastasis-prone condition. [Nature]

Identification of a Tumor Suppressor Relay Between the FOXP3 and the Hippo Pathways in Breast and Prostate Cancers
Scientists report that spontaneous mutation of the transcription factor FOXP3 reduces expression of the LATS2 gene in mammary epithelial cells. [Cancer Res]

Energy Restriction-Mimetic Agents Induce Apoptosis in Prostate Cancer Cells, in part, Through Epigenetic Activation of KLF6 Tumor Suppressor Gene Expression
By using a novel thiazolidinedione-derived energy restriction-mimetic agent (ERMA), CG12 [J Biol Chem (2010) 285, 9780], vis-a-vis 2-deoxyglucose and glucose deprivation, researchers obtain evidence that epigenetic activation of the tumor suppressor gene Kruppel-like factor 6 plays a pivotal role in ERMA-induced apoptosis in prostate cancer cells. [J Biol Chem]

Lipoprotein Lipase Links Dietary Fat to Solid Tumor Cell Proliferation
Scientists hypothesized that, in addition to synthesis, cancer cells may obtain pre-formed, diet-derived fatty acids by uptake from the bloodstream. [Mol Cancer Ther]

Targeted Inhibition of Mitochondrial Hsp90 Suppresses Localised and Metastatic Prostate Cancer Growth in a Genetic Mouse Model of Disease
Investigators tested the efficacy of a novel mitochondrial-targeted, small-molecule Hsp90 inhibitor, Gamitrinib (GA mitochondrial matrix inhibitor), in the Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) model. [Br J Cancer]

In Vitro and In Vivo Anticancer Action of Saquinavir-NO, a Novel Nitric Oxide-Derivative of the Protease Inhibitor Saquinavir, on Hormone Resistant Prostate Cancer Cells
Scientists evaluated the in vitro and in vivo activity of saquinavir-NO (Saq-NO) on the p53-deficient hormone resistant prostate cancer PC-3 cells. [Cell Cycle]

Ethanolic Extract of Brazilian Green Propolis Sensitizes Prostate Cancer Cells to TRAIL-Induced Apoptosis
Researchers examined the cytotoxic and apoptotic effects of Brazilian green propolis and its bioactive components in combination with tumor necrosis factor-related apoptosis (TRAIL) on LNCaP prostate cancer cells. [Int J Oncol]

Co-Delivery of PSA and PSMA DNA Vaccines With Electroporation Induces Potent Immune Responses
Scientists sought to test the hypothesis that a broader collection of antigens would improve the breadth and effectiveness of a prostate cancer (PCa) immune therapy approach. They developed highly optimized DNA vaccines encoding prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) as a dual antigen approach to immune therapy of PCa. [Hum Vaccin]

CLINICAL RESEARCH

A Multi-Centre Randomised Phase III Trial of Dexamethasone vs Dexamethasone and Diethylstilbestrol in Castration-Resistant Prostate Cancer: Immediate vs Deferred Diethylstilbestrol
Investigators performed a multi-centre randomised phase III study comparing the use of Dexamethasone, Aspirin, and immediate addition of Diethylstilbestrol vs Dexamethasone, Aspirin, and deferred (until disease progression) addition of Diethylstilbestrol. [Br J Cancer]

Docetaxel and Epirubicin Compared with Docetaxel and Prednisone In Advanced Castrate-Resistant Prostate Cancer: A Randomised Phase II Study
This randomised phase II study compared the activity and safety of the combination docetaxel (D)/epirubicin with the conventional treatment D/prednisone in advanced castrate-resistant prostate cancer patients. [Br J Cancer]



INDUSTRY NEWS

Mayo Clinic Receives $100 Million Gift to Support Proton Beam Therapy Program
Mayo Clinic announced long-time patient and philanthropist Richard O. Jacobson has given a $100 million gift to help establish the multi-site Mayo Clinic Proton Beam Therapy Program. [Mayo Clinic Press Release]

Endo Pharmaceuticals and Orion Corporation Begin Novel R&D Collaboration
Endo Pharmaceuticals announced that it has entered into a collaboration agreement with European-based Orion Corporation for the discovery, development and commercialization of assets in Oncology. [Endo Pharmaceuticals Press Release]

Sanofi Fails to Block Sale of Taxotere Generics in Australia
Sanofi-Aventis SA failed to block two generic drug manufacturers from selling a copy of the cancer drug Taxotere in Australia, with a federal court judge refusing to bar the sale of the generics. [Bloomberg Businessweek]






Learn more about Prostate Cell News: Archives  |  Events  |  Subscribe  |  Contact Us